Finance

Lists
Q3 2026 earnings • released • EPS miss -1.83%
See results
EVMN:NYSE
Evommune Inc
$8.02
-7.18%
(-0.62) 1D
$7.88
-1.75% (-0.14)
After hours
Closed: Nov 12, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EVMN...
Open
$8.58
High
$8.58
Low
$7.74
Mkt. cap
291.06M
Avg. vol.
994.07K
Volume
0.00
52-wk high
$33.20
52-wk low
$4.94
EPS
-$2.89
Shares outstanding
36.29M
No. of employees
48
Open
$8.58
High
$8.58
Low
$7.74
Mkt. cap
291.06M
Avg. vol.
994.07K
Volume
0.00
52-wk high
$33.20
52-wk low
$4.94
EPS
-$2.89
Shares outstanding
36.29M
No. of employees
48
News stories
From web sources and news partners
About Evommune Inc
CEO-
Employees48
Founded2020
HeadquartersPalo Alto, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteevommune.com
Analyst ratings
Based on 11 analysts giving stock ratings to EVMN in the past 3 months
Buy
Buy
8
Hold
3
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for EVMN in the last 3 months.
Highest
Current $8.02
$30.00 (+274.06%)
Average
$22.00 (+174.31%)
Lowest
$8.00 (-0.25%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$30.00
+274.1%
11/05/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Maintained
-
-
11/02/2026
Alice Nettleton
UBS
Hold
Initiated
$8.00
-0.2%
10/11/2026
Unknown Analyst
UBS
Hold
Initiated
$8.00
-0.2%
10/11/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Maintained
-
-
09/17/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$23.00
+186.8%
09/09/2026
Serge Belanger
Needham
Buy
Maintained
$28.00
+249.1%
09/09/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
$22.00
+174.3%
09/10/2026
Martin Auster
Raymond James
Buy
Maintained
$18.00
+124.4%
09/09/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
$26.00
+224.2%
09/09/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$21.00
+161.8%
09/08/2026
Matt Phipps
William Blair
Hold
Maintained
-
-
09/09/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$22.00
+174.3%
08/10/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$26.00
+224.2%
08/10/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.85 / -$0.83
-1.83%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
10.00M
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
19.64M
20.40M
17.32M
26.41M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.69M
9.31M
6.64M
8.48M
Operating expense
23.33M
29.72M
23.95M
34.90M
Total operating expenses
23.33M
29.72M
23.95M
34.90M
Operating income
-13.33M
-29.72M
-23.95M
-34.90M
Other non operating income
-9.00K
-
-4.00K
-2.00K
EBT including unusual items
-12.48M
-28.27M
-21.67M
-32.25M
EBT excluding unusual items
-12.48M
-28.27M
-21.67M
-32.25M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.48M
-28.27M
-21.67M
-32.25M
Net profit margin
-124.75%
-
-
-
Earnings per share
-8.07
-1.43
-0.64
-0.89
Interest and investment income
862.00K
1.44M
2.28M
2.65M
Interest expense
-
-
-
-
Net interest expenses
862.00K
1.44M
2.28M
2.65M
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.02M
-29.39M
-23.60M
-34.34M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps